- Home
- PNI vs MGNX Comparison
PNI vs MGNX Comparison
Compare PNI & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- MGNX
- Stock Information
- Founded
- PNI 2002
- MGNX 2000
- Country
- PNI United States
- MGNX United States
- Employees
- PNI N/A
- MGNX N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- PNI Finance
- MGNX Health Care
- Exchange
- PNI Nasdaq
- MGNX Nasdaq
- Market Cap
- PNI 75.2M
- MGNX 87.7M
- IPO Year
- PNI N/A
- MGNX 2013
- Fundamental
- Price
- PNI $6.77
- MGNX $1.38
- Analyst Decision
- PNI
- MGNX Hold
- Analyst Count
- PNI 0
- MGNX 9
- Target Price
- PNI N/A
- MGNX $5.33
- AVG Volume (30 Days)
- PNI 26.4K
- MGNX 2.6M
- Earning Date
- PNI 01-01-0001
- MGNX 08-05-2025
- Dividend Yield
- PNI 4.76%
- MGNX N/A
- EPS Growth
- PNI N/A
- MGNX N/A
- EPS
- PNI N/A
- MGNX N/A
- Revenue
- PNI N/A
- MGNX $154,050,000.00
- Revenue This Year
- PNI N/A
- MGNX N/A
- Revenue Next Year
- PNI N/A
- MGNX N/A
- P/E Ratio
- PNI N/A
- MGNX N/A
- Revenue Growth
- PNI N/A
- MGNX 255.31
- 52 Week Low
- PNI $6.03
- MGNX $0.99
- 52 Week High
- PNI $7.89
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- PNI 57.94
- MGNX 48.17
- Support Level
- PNI $6.61
- MGNX $1.19
- Resistance Level
- PNI $6.71
- MGNX $1.41
- Average True Range (ATR)
- PNI 0.06
- MGNX 0.11
- MACD
- PNI 0.01
- MGNX -0.01
- Stochastic Oscillator
- PNI 100.00
- MGNX 39.39
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.